RSbiomed   Report issue

For profit Phase 2
Founded: Williamston MI United States (1994)
Status: No NME R&D (1994)

Organization Overview

First Clinical Trial
2013
NCT01868906
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

fluoromisonidazole (1 trial)

temozolomide (temodar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2